Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028652 · ClinicalTrials.gov registry record · Phase 1
Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00028652 is a Phase 1 study that was terminated before completion, run by University of Wisconsin, Madison.
The verdict
NCT00028652, a Phase 1 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Inserting the gene for interleukin-12 into a person's skin tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 gene therapy in treating patients who have skin metastases.
Interventions
- BIOLOGICAL interleukin-12 gene
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028652
The ClinicalTrials.gov registry entry for NCT00028652 describes a study currently listed as terminated, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which interleukin-12 gene is the first listed.
NCT00028652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00028652 about?
NCT00028652 is a clinical study titled "Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases". RATIONALE: Inserting the gene for interleukin-12 into a person's skin tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 gene therapy in treating patients who have skin metastases.
What is the current status of trial NCT00028652?
This trial is currently terminated. It is a Phase 1 study. The study started on 2002-01.
What interventions are being tested in trial NCT00028652?
The interventions under investigation include: interleukin-12 gene (BIOLOGICAL).
Who is sponsoring clinical trial NCT00028652?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.